The Canadian company reported adjusted earnings per share of four cents in Q2, versus a loss of five cents in Q2 2022) shares also saw gains after beating third-quarter profit
estimates, but lowering its full-year guidance. The drugmaker is gaining momentum from its diabetes drug Mounjaro, though it still lacks regulatory approval for obesity treatment.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: